Three-dimensional printing of chitosan cryogel as injectable and shape recoverable scaffolds.
Chen TC., Wong CW., Hsu SH.
Laboratory Study, published in Carbohydr Polym (2022) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Laboratory Study
- Journal
- Carbohydr Polym (2022)
- Country
- England
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 35287856
- DOI
- 10.1016/j.carbpol.2022.119228
Abstract (original English)
Cryogel has macroporous structure and advantages of mechanical stability and injectability for biomedical applications. Three-dimensional (3D) printing is a customized manufacturing technology. However, there is little research on 3D printing of cryogel. In this work, we developed a 3D-printable chitosan cryogel using difunctional polyurethane nanoparticles as the crosslinker that reacted with chitosan at 4 °C for 4 h to form a stable feeding hydrogel (pre-cryogel) for 3D printing. The printed pre-cryogel was frozen at -20 °C to form 3D-printed chitosan cryogel. The 3D-printed cryogel had properties similar to those of bulk cryogel such as high compressibility, elastic recovery, and water absorption (≈3200%). Results from cell experiments indicated that the 3D-printed chitosan cryogel scaffolds provided good mechanical integrity for proliferation and chondrogenic differentiation of human adipose-derived adult stem cells. The 3D-printed chitosan cryogel scaffolds with injectability and shape recovery property are potential biomaterials for customized tissue engineering and minimally invasive surgery.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.